Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092 von Yu, Yi, Savage, Ronald E, Eathiraj, Sudharshan, Meade, Justin, Wick, Michael J, Hall, Terence, Abbadessa, Giovanni, Schwartz, Brian

Volltext

Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling von Andersson, Mattias K, Afshari, Maryam K, Andrén, Ywonne, Wick, Michael J, Stenman, Göran

Volltext

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma von Drier, Yotam, Cotton, Matthew J, Williamson, Kaylyn E, Gillespie, Shawn M, Ryan, Russell J H, Kluk, Michael J, Carey, Christopher D, Rodig, Scott J, Sholl, Lynette M, Afrogheh, Amir H, Faquin, William C, Queimado, Lurdes, Qi, Jun, Wick, Michael J, El-Naggar, Adel K, Bradner, James E, Moskaluk, Christopher A, Aster, Jon C, Knoechel, Birgit, Bernstein, Bradley E

Volltext

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Res... von Ferrarotto, Renata, Mitani, Yoshitsugu, Diao, Lixia, Guijarro, Irene, Wang, Jing, Zweidler-McKay, Patrick, Bell, Diana, William, Jr, William N, Glisson, Bonnie S, Wick, Michael J, Kapoun, Ann M, Patnaik, Amita, Eckhardt, Gail, Munster, Pamela, Faoro, Leonardo, Dupont, Jakob, Lee, J Jack, Futreal, Andrew, El-Naggar, Adel K, Heymach, John V

Volltext

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer von Hidalgo, Manuel, Bruckheimer, Elizabeth, Rajeshkumar, N V, Garrido-Laguna, Ignacio, De Oliveira, Elizabeth, Rubio-Viqueira, Belen, Strawn, Steven, Wick, Michael J, Martell, James, Sidransky, David

Volltext

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads von Kinneer, Krista, Meekin, John, Tiberghien, Arnaud C, Tai, Yu-Tzu, Phipps, Sandrina, Kiefer, Christine Mione, Rebelatto, Marlon C, Dimasi, Nazzareno, Moriarty, Alyssa, Papadopoulos, Kyriakos P, Sridhar, Sriram, Gregson, Stephen J, Wick, Michael J, Masterson, Luke, Anderson, Kenneth C, Herbst, Ronald, Howard, Philip W, Tice, David A

Volltext

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer von SHIMIZU, Toshio, TOLCHER, Anthony W, WICK, Michael J, ALVAREZ, Cathy, CAVAZOS, Aracely, MANGOLD, Gina L, PATNAIK, Amita, PAPADOPOULOS, Kyriakos P, BEERAM, Muralidhar, RASCO, Drew W, SMITH, Lon S, GUNN, Shelly, SMETZER, Leslie, MAYS, Theresa A, KAISER, Brianne

Volltext

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) von Germann, Ursula A, Furey, Brinley F, Markland, William, Hoover, Russell R, Aronov, Alex M, Roix, Jeffrey J, Hale, Michael, Boucher, Diane M, Sorrell, David A, Martinez-Botella, Gabriel, Fitzgibbon, Matthew, Shapiro, Paul, Wick, Michael J, Samadani, Ramin, Meshaw, Kathryn, Groover, Anna, DeCrescenzo, Gary, Namchuk, Mark, Emery, Caroline M, Saha, Saurabh, Welsch, Dean J

Volltext

Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma von Mandelbaum, Joseph, Shestopalov, Ilya A, Henderson, Rachel E, Chau, Nicole G, Knoechel, Birgit, Wick, Michael J, Zon, Leonard I

Volltext

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma von Capone, Emily, Perrotti, Vittoria, Cela, Ilaria, Lattanzio, Rossano, Togni, Lucrezia, Rubini, Corrado, Caponio, Vito Carlo Alberto, Lo Muzio, Lorenzo, Colasante, Martina, Giansanti, Francesco, Ippoliti, Rodolfo, Iacobelli, Stefano, Wick, Michael J, Spardy Burr, Nicole, Sala, Gianluca

Volltext

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor von Yu, Yi, Hall, Terence, Eathiraj, Sudharshan, Wick, Michael J, Schwartz, Brian, Abbadessa, Giovanni

Volltext

Theoretical and phenomenological constraints on form factors for radiative and semi-leptonic B-meson decays von Bharucha, Aoife, Feldmann, Thorsten, Wick, Michael

Volltext

A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug von Chen, Chen, Choudhury, Sujata, Wangsa, Darawalee, Lescott, Chamille J., Wilkins, Devan J., Sripadhan, Praathibha, Liu, Xuefeng, Wangsa, Danny, Ried, Thomas, Moskaluk, Christopher, Wick, Michael J., Glasgow, Eric, Schlegel, Richard, Agarwal, Seema

Volltext

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft von Morelli, M Pia, Calvo, Emiliano, Ordoñez, Esther, Wick, Michael J, Viqueira, Belen-Rubio, Lopez-Casas, Pedro P, Bruckheimer, Elizabeth, Calles-Blanco, Antonio, Sidransky, David, Hidalgo, Manuel

Volltext

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers von Sudhan, Dhivya R., Guerrero-Zotano, Angel, Won, Helen, González Ericsson, Paula, Servetto, Alberto, Huerta-Rosario, Mariela, Ye, Dan, Lee, Kyung-min, Formisano, Luigi, Guo, Yan, Liu, Qi, Kinch, Lisa N., Red Brewer, Monica, Dugger, Teresa, Koch, James, Wick, Michael J., Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Hanker, Ariella B., Arteaga, Carlos L.

Volltext

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer von Ali, Zaheer, Vildevall, Malin, Rodriguez, Gabriela Vazquez, Tandiono, Decky, Vamvakaris, Ioannis, Evangelou, Georgios, Lolas, Georgios, Syrigos, Konstantinos N, Villanueva, Alberto, Wick, Michael, Omar, Shenga, Erkstam, Anna, Schueler, Julia, Fahlgren, Anna, Jensen, Lasse D

Volltext

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms von Walker, Christopher J., Chang, Hua, Henegar, Leah, Kashyap, Trinayan, Shacham, Sharon, Sommer, Josh, Wick, Michael J., Levy, Joan, Landesman, Yosef

Volltext

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors von Calvo, Emiliano, Soria, Jean-Charles, Ma, Wen Wee, Wang, Tao, Bahleda, Rastilav, Tolcher, Anthony W, Gernhardt, Diana, O'Connell, Joseph, Millham, Robert, Giri, Nagdeep, Wick, Michael J, Adjei, Alex A, Hidalgo, Manuel

Volltext

ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma von Andersson, Mattias K., Mangiapane, Giovanna, Nevado, Paloma Tejera, Tsakaneli, Alexia, Carlsson, Therese, Corda, Gabriele, Nieddu, Valentina, Abrahamian, Carla, Chayka, Olesya, Rai, Lilam, Wick, Michael, Kedaigle, Amanda, Stenman, Göran, Sala, Arturo

Volltext

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer von Furman, Craig, Puyang, Xiaoling, Zhang, Zhaojie, Wu, Zhenhua J, Banka, Deepti, Aithal, Kiran B, Albacker, Lee A, Hao, Ming-Hong, Irwin, Sean, Kim, Amy, Montesion, Meagan, Moriarty, Alyssa D, Murugesan, Karthikeyan, Nguyen, Tuong-Vi, Rimkunas, Victoria, Sahmoud, Tarek, Wick, Michael J, Yao, Shihua, Zhang, Xun, Zeng, Hao, Vaillancourt, Frédéric H, Bolduc, David M, Larsen, Nicholas, Zheng, Guo Zhu, Prajapati, Sudeep, Zhu, Ping, Korpal, Manav

Volltext